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Subcutaneous Injection of Large Volumes of Polidocanol
Sclerotherapy is a standard treatment of varicose veins
and telangiectasias.1 Different sclerosing agents have
been used, with sodium tetradecyl sulfate (STS) and
polidocanol (POL) being the most frequent molecules.
Both solutions are detergents andmay be emulsiﬁed to
produce foam, which will increase the potency over 2-
fold and decrease toxicity 4-fold.
The risk of local complications after injection of POL
seems relatively low. Cutaneous ulcerations have been
reportedbetween0.2%and1.2%of cases.The authors
here report the case of a patient who was erroneously
administered a high volume of POL as local anesthetic
with no major and long-lasting complication.
Observation
A 19-year-old female patient presented with a pig-
mented lesion on her right forearm. On clinical
examination anddermoscopy, the lesion showed some
atypical features and was therefore excised to rule out
melanoma. The patient was subcutaneously injected
with a 7-mL solution of an anesthetic thought to rep-
resent lidocaine plus epinephrine. Because no signiﬁ-
cant anesthetic and vasoconstrictor effect was
observed after 10 minutes, the physician ﬁnally real-
ized to have erroneously used a 0.5% POL solution
instead and canceled the planned excision after
informing the patient about the mistake. There were
no acute local or systemic adverse effects. Over the
following days, the patient developed a slight painful
and warm local tumefaction at the site of injection.
The ultrasound examination revealed a subcutaneous
edematous swelling (Figure 1). At no point did the
patient or physician observe any loss of subcutaneous
tissue or signs of fat atrophy. The lesion was ﬁnally
excised 6 weeks later and light microscopy studies
showed the presence of a dysplastic melanocytic nevus
with an underlying moderate, lobular panniculitis.
There was no evidence for either necrosis or vascular
occlusion (Figure 2).
Figure 1. Transversal sonographic image of the left (L) and right (R) forearms, 2 weeks after injection of 7 mL of 0.5%
polidocanol showing an edematous, subcutaneous swelling on the right forearm.
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Discussion
Tissue necrosis may occur after sclerotherapy with
various sclerosing agents.1 This complication is rare
and typically observed with caustic solutions such as
hypertonic saline. The exact mechanisms responsible
for cutaneous necrosis remain unclear. A variety of
factors have been discussed such as direct toxic
effects of the extravasated molecules, vascular
occlusion due to intra-arteriolar injection, reactive
vasospasm, or injection of arteriovenous shunts,
which may variably result in tissue hypoxia and tis-
sue destruction.1
Polidocanol, which was introduced in 1936 as a local
and topical anesthetic,1 is still used today in some der-
matological and proctological creams and ointments.
Previous experimental studies have shown that sub-
cutaneous injection of POL may lead to damage of
muscle cells of the tunica intima andmedia of the blood
vessels as well as, to some extent, myelinated axons of
the paravascular nerves.1,2 However, the surrounding
tissues did not seem to be signiﬁcantly damaged. These
observations contributed to the commercialization of
POL as a sclerosing agent.Other reports underlined the
safety of POL up to 3%, even after extravascular
injection in rats and in rabbits.3,4 In humans, local
edema was observed after 4 accidental injections of
POL (1–2 mL, 0.5%–2%), without late complications
(Kreussler Pharmaceuticals, unpublished data).1 How-
ever this risk seems to be different with STS as showed
by Duffy, where deliberate mid-dermal injection of 0.4
mL of 3% POL did not induce tissue necrosis, but 0.4
mL of 1% STS did.1
In the authors’ patient, inﬁltrationwith 7mLof 0.5%
of POL resulted in a moderate swelling and localized
painful sensation. Although a clinical and histologi-
cal panniculitis was visible, no damage or necrosis of
dermal vessels and the subcutaneous tissue was
observed.
Nonetheless, the effects of higher concentrations of
POL extravasate are more unpredictable. The
authors observed the development of a severe Nic-
olau dermatitis 4 days after ultrasound-guided scle-
rotherapy with 4 mL of 2% POL foam.1 This delayed
reaction might be due to an arterial vasospasm after
POL’s transparietal diffusion. The POL-related ves-
sel wall damage after paravasal injection has also
been therapeutically used, such as for the manage-
ment of red telangiectasias (“Quaddeln”)1 and ante-
rior epistaxis.5 The effects of these proceduresmay be
related to the toxic effect of POL while diffusing
through the vessel walls.
Even if accidental paravasal injection may be well
tolerated, it is important that the managing physician
is familiar with the injection techniques and carefully
considers the available guidelines to limit the risk of
iatrogenic complications.
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Figure 2. Dysplastic melanocytic nevus (A) with an underlying panniculitis but no tissue necrosis (B) 4 weeks after sub-
cutaneous injection of 7 mL of 0.5% polidocanol.
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